Surgical Science Sweden AB (SUS) Fair Value & Analysis
Healthcare · SE · Market cap 1.5B SEK
Fair value as of: Jul 18, 2026
From 24 valuation models · updated 23 days ago
Fair value updated Jul 18, 2026, revised from kr 39.81 to kr 28.81 (−27.6%) since Jun 24, 2026. Share price +23.9% over the past month.
A solid business, but screening 24% overvalued on our models.
What matters now
- The price sits above even our optimistic bull case (kr 36.01). The favourable scenario is already priced in.
- Solid but not exceptional quality (61/100) and above fair value, neither a clear bargain nor a standout compounder.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jul 18, 2026.
How to read this chart
60‑month range kr 23.92 – kr 324.75 · fair‑value band kr 25.05 – kr 36.01 · the kr 38.12 price screens above the kr 28.81 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Jul 18, 2026.
Analysis
Surgical Science Sweden AB (SUS) currently trades at kr 38.12, while our model-based Fair Value estimate is kr 28.81, implying the stock looks roughly 24.4% overvalued today. The Quality Score stands at 61/100 (solid quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: high).
Over the trailing twelve months, Surgical Science Sweden AB generated revenue of 977M SEK at a net margin of 5.3%. Revenue declined 6.1% year over year. It earns a return on equity of 1.2%. The balance sheet holds a net cash position of 615M SEK. Fundamentals as of Jul 18, 2026
Our scenario range runs from kr 25.05 (bear case) to kr 36.01 (bull case); at kr 38.12, the current price sits above that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 77% below its 52-week high and 61% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -53% fair-value upside, at -24%, SUS screens cheaper than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 24 models by family
Widest divergence: Growth Earnings (kr 58.40) versus Economic Profit (kr 25.53). Highest evidence: Growth DCF (80).
Notify me when SUS reaches fair value
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Jul 18, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 60 · Market factors (momentum, volatility) 39
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
Surgical Science Sweden AB (publ) develops and markets virtual reality simulators and customized training solutions for evidence-based medical training in Europe, North and South America, Asia, and internationally.
Full company description
Surgical Science Sweden AB (publ) develops and markets virtual reality simulators and customized training solutions for evidence-based medical training in Europe, North and South America, Asia, and internationally. The company offers Angio Mentor simulator for endovascular training; BRONCH Express, a portable version of BRONCH mentor simulator; ARTHRO Mentor for arthroscopic surgery skills acquisition; BRONCH Mentor, a simulator for optimizing bronchoscopy training; GI Mentor, a simulator for GI Endoscopy; HYST Mentor for True-To-Life diagnostic and therapeutic hysteroscopy training; URO Mentor, a virtual reality simulator for endourology training; EndoSim, a realistic scope simulator; FlexVR, a flexible and portable training platform which is designed to teach basic and advanced skills for robotic surgery; and LAP Mentor provides a wide array of laparoscopic training cases. It also provides LapSim training system comprising LapSim Haptic simulator that provides laparoscopic training; LapSim essence, a portable and ready-to-use VR simulator; and LapSim 360, which provides a high-immersion virtual reality training experience; MentorLearn, an end-to-end educational platform that makes simulation course management; and LapSim ST, a training system that prepares students for the operating room. In addition, the company offers PELVIC Mentor simulator provides anatomy and pelvic exam training; Perc Mentor suite for image-guided interventions; RobotiX Mentor for practice the motor and cognitive skills for surgeons; Simball Box, which combines with digitally collected metrics into a training tool; Spine Mentor, a training simulator for minimal invasive spine surgery; TEE Express, designed to teach Trans-Esophageal Echocardiography procedure using a TEE probe; TraumaVR, an ultimate mix of manikin and VR simulation; and Ultrasound Mentor for ultrasound training with multiple medical specialties. Surgical Science AB was founded in 1997 and is based in Gothenburg, Sweden.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Surgical Science Sweden AB reported revenue of kr 992M in FY2025 versus kr 367M in FY2021, a compound +28.3%/yr. Reported net income was kr 66.8M in FY2025, compounding −6.2%/yr from FY2021.
SUS screens 24% overvalued. Compare with Veeva Systems Inc →
Peer Group
Health Information Services · 126 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Health Information Services median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Health Information Services stocks, each showing price versus our Fair Value estimate (as of Jul 18, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Veeva Systems Inc VEEV | $190.12 | $95.12 | -50% |
| Pro Medicus Limited PME | A$194.84 | A$23.74 | -88% |
| BrightSpring Health Services, Inc BTSG | $68.16 | $21.31 | -69% |
| HealthEquity, Inc HQY | $97.67 | $56.63 | -42% |
| Hinge Health, Inc HNGE | $88.80 | $24.03 | -73% |
| 10x Genomics, Inc TXG | $45.75 | $17.18 | -62% |
| Waystar Holding WAY | $22.69 | $12.86 | -43% |
| Doximity, Inc DOCS | $22.21 | $17.18 | -23% |
| Privia Health Group PRVA | $28.10 | $5.30 | -81% |
| Inventurus Knowledge Solutions Limited IKS | ₹1,846 | ₹860.28 | -53% |
Compare Surgical Science Sweden AB with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Surgical Science Sweden AB (SUS) overvalued or undervalued?
What is the fair value of SUS?
What is the quality score of SUS?
What is the revenue of Surgical Science Sweden AB (SUS)?
What is the net profit margin of SUS?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track Surgical Science Sweden AB and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.